Journal Home > Volume 20 , Issue 5
Cancer Biology & Medicine 2023, 20(5): 344-352 https://doi.org/10.20892/j.issn.2095-3941.2023.0012
Review | Open Access | Issue | Published: 05 June 2023

Expert opinion on translational research for advanced glioblastoma treatment

Show Author's Information Xiaoteng Cui,  Yunfei Wang,  Junhu Zhou,  Qixue Wang,  Chunsheng Kang ( )
Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital, Tianjin 300052, China
Keywords:
glioblastoma, temozolomide, Malignant gliomas, chemoresistance, small molecule drugs
Cite this article:
Cui X, Wang Y, Zhou J, et al. Expert opinion on translational research for advanced glioblastoma treatment. Cancer Biology & Medicine, 2023, 20(5): 344-352. https://doi.org/10.20892/j.issn.2095-3941.2023.0012
Download citation
EndNote(RIS)
BibTeX

248

Views

13

Downloads

Citations

1

Crossref

7

WoS

5

Scopus

N/A

CSCD

Abstract Full text About this article

Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat because of the infiltrative growth pattern, rapid progression, and poor prognosis. Many antitumor drugs are not ideal for the treatment of gliomas due to the blood-brain barrier. Temozolomide(TMZ) is a DNA alkylating agent that can cross the blood-brain barrier. As the only first-line chemotherapeutic drug for malignant gliomas at present, TMZ is widely utilized to provide a survival benefit; however, some patients are inherently insensitive to TMZ. In addition, patients could develop acquired resistance during TMZ treatment, which limits antitumor efficacy. To clarify the mechanism underlying TMZ resistance, numerous studies have provided multilevel solutions, such as improving the effective concentration of TMZ in tumors and developing novel small molecule drugs. This review discusses the in-depth mechanisms underlying TMZ drug resistance, thus aiming to provide possibilities for the establishment of personalized therapeutic strategies against malignant gliomas and the accelerated development and transformation of new targeted drugs.


menu
Abstract
Full text
Outline
About this article

Expert opinion on translational research for advanced glioblastoma treatment

Show Author's information Xiaoteng Cui, Yunfei Wang, Junhu Zhou, Qixue Wang, Chunsheng Kang ( )
Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital, Tianjin 300052, China

Abstract

Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat because of the infiltrative growth pattern, rapid progression, and poor prognosis. Many antitumor drugs are not ideal for the treatment of gliomas due to the blood-brain barrier. Temozolomide(TMZ) is a DNA alkylating agent that can cross the blood-brain barrier. As the only first-line chemotherapeutic drug for malignant gliomas at present, TMZ is widely utilized to provide a survival benefit; however, some patients are inherently insensitive to TMZ. In addition, patients could develop acquired resistance during TMZ treatment, which limits antitumor efficacy. To clarify the mechanism underlying TMZ resistance, numerous studies have provided multilevel solutions, such as improving the effective concentration of TMZ in tumors and developing novel small molecule drugs. This review discusses the in-depth mechanisms underlying TMZ drug resistance, thus aiming to provide possibilities for the establishment of personalized therapeutic strategies against malignant gliomas and the accelerated development and transformation of new targeted drugs.

Keywords: glioblastoma, temozolomide, Malignant gliomas, chemoresistance, small molecule drugs

References(87)

1

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2015-2019. Neuro Oncol. 2022; 24(Suppl 5): v1-95.
DOI Google Scholar
2

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359: 492-507.
DOI Google Scholar
3

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23: 1231-51.
DOI Google Scholar
4

Stylli SS. Novel treatment strategies for glioblastoma. Cancers(Basel). 2020; 12: 2883.
DOI Google Scholar
5

Chen C, Xu T, Lu Y, Chen J, Wu S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol. 2013; 20: 223-30.
DOI Google Scholar
6

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008; 14: 2900-8.
DOI Google Scholar
7

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-66.
DOI Google Scholar
8

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017; 376: 1027-37.
DOI Google Scholar
9

Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one(CCRG 81045; M & B 39831), a novel drug with potential as analternative to dacarbazine. Cancer Res. 1987; 47: 5846-52.
Google Scholar
10

Cohen MH, Johnson JR, Pazdur R. Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005; 11(19 Pt 1): 6767-71.
DOI Google Scholar
11

Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016; 3: 198-210.
DOI Google Scholar
12

Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev. 2012; 64: 590-7.
DOI Google Scholar
13

Knisely JP, Baehring JM. A silver lining on the horizon for glioblastoma. Lancet Oncol. 2009; 10: 434-5.
DOI Google Scholar
14

Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010; 10: 319-31.
DOI Google Scholar
15

Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, et al. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers(Basel). 2019; 11: 174.
DOI Google Scholar
16

Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, et al. Mutational landscape of secondary glioblastoma guides met-targeted trial in brain tumor. Cell. 2018; 175: 1665-78.e18.
DOI Google Scholar
17

Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017; 133: 455-67.
DOI Google Scholar
18

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvⅢ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017; 9: eaaa0984.
DOI Google Scholar
19

Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res. 1999; 5: 1629-37.
Google Scholar
20

Fuchs RP, Isogawa A, Paulo JA, Onizuka K, Takahashi T, Amunugama R, et al. Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide. Elife. 2021; 10: e69544.
DOI Google Scholar
21

Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001; 61: 1957-63.
Google Scholar
22

Shen HY, Tang HL, Zheng YH, Feng J, Dong BX, Chen XQ. The PARP1 inhibitor niraparib represses DNA damage repair and synergizes with temozolomide for antimyeloma effects. J Oncol. 2022; 2022: 2800488.
DOI Google Scholar
23

Alonso MM, Gomez-Manzano C, Bekele BN, Yung WKA, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007; 67: 11499-504.
DOI Google Scholar
24

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018; 18: 452-64.
DOI Google Scholar
25

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999; 39: 361-98.
DOI Google Scholar
26

Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 2015; 367: 69-75.
DOI Google Scholar
27

Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, et al. Expression of multidrug-resistance P-glycoprotein(MDR1) in human brain tumors. Int J Cancer. 2001; 93: 62-6.
DOI Google Scholar
28

Yang E, Wang L, Jin W, Liu X, Wang Q, Wu Y, et al. PTRF/Cavin-1enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma. Theranostics. 2022; 12: 4330-47.
DOI Google Scholar
29

Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CFM, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007; 26: 186-97.
DOI Google Scholar
30

Atkins RJ, Ng W, Stylli SS, Hovens CM, Kaye AH. Repair mechanisms help glioblastoma resist treatment. J Clin Neurosci. 2015; 22: 14-20.
DOI Google Scholar
31

Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, et al. MSH6mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009; 15: 4622-9.
DOI Google Scholar
32

Erasimus H, Gobin M, Niclou S, Van Dyck E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Rev Mutat Res. 2016; 769: 19-35.
DOI Google Scholar
33

Zharkov DO. Base excision DNA repair. Cell Mol Life Sci. 2008; 65: 1544-65.
DOI Google Scholar
34

Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021; 23: 920-31.
DOI Google Scholar
35

Sim HW, Galanis E, Khasraw M. PARP inhibitors in glioma: a review of therapeutic opportunities. Cancers (Basel). 2022; 14: 1003.
DOI Google Scholar
36

Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated hypermutation in gliomas. Neuro Oncol. 2018; 20: 1300-9.
DOI Google Scholar
37

Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMTand the clinical response of gliomas to alkylating agents. N Engl JMed. 2000; 343: 1350-4.
DOI Google Scholar
38

Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, et al. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020; 6: 380-91.
DOI Google Scholar
39

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
DOI Google Scholar
40

Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanineDNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998; 16: 3851-7.
DOI Google Scholar
41

Wu P, Cai J, Chen Q, Han B, Meng X, Li Y, et al. Lnc-TALCpromotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with mi R-20b-3p. Nat Commun. 2019; 10: 2045.
DOI Google Scholar
42

Zhao J, Yang S, Cui X, Wang Q, Yang E, Tong F, et al. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma. Neuro Oncol. 2022; noac242.
DOI Google Scholar
43

Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, et al. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med. 2021; 18: 272-82.
DOI Google Scholar
44

Rosch L, Herter S, Najafi S, Ridinger J, Peterziel H, Cinatl J, et al. ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Mol Oncol. 2023; 17: 37-58.
DOI Google Scholar
45

Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase IOPARATIC trial. Neuro Oncol. 2020; 22: 1840-50.
DOI Google Scholar
46

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155: 462-77.
DOI Google Scholar
47

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17: 98-110.
DOI Google Scholar
48

Wang Z, Bao Z, Yan W, You G, Wang Y, Li X, et al. Isocitrate dehydrogenase 1 (IDH1) mutation-specific micro RNA signature predicts favorable prognosis in glioblastoma patients with IDH1wild type. J Exp Clin Cancer Res. 2013; 32: 59.
DOI Google Scholar
49

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERTpromoter mutations in tumors. N Engl J Med. 2015; 372: 2499-508.
DOI Google Scholar
50

Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, et al. Pan-cancer efficacy of vemurafenib in BRAFv600-mutant nonmelanoma cancers. Cancer Discov. 2020; 10: 657-63.
DOI Google Scholar
51

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012; 131: 1342-50.
DOI Google Scholar
52

Mo Z, Xin J, Chai R, Woo PYM, Chan DTM, Wang J. Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. Cancer Biol Med. 2022; 19: 1440-59.
DOI Google Scholar
53

Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017; 68: 139-52.
DOI Google Scholar
54

Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022; 40: 586-97.
DOI Google Scholar
55

Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021; 398: 1002-14.
DOI Google Scholar
56

Lee EQ. Immune checkpoint inhibitors in GBM. J Neurooncol. 2021; 155: 1-11.
DOI Google Scholar
57

Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018; 9: 300-5.
DOI Google Scholar
58

Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, et al. Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett. 2020; 11: 101-7.
DOI Google Scholar
59

Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, et al. ACT001reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020; 10: 5943-56.
DOI Google Scholar
60

Wang Q, Liu X, Zhou J, Yang C, Wang G, Tan Y, et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv Sci (Weinh). 2019; 6: 1901299.
DOI Google Scholar
61

Seliger C, Luber C, Gerken M, Schaertl J, Proescholdt M, Riemenschneider MJ, et al. Use of metformin and survival of patients with high-grade glioma. Int J Cancer. 2019; 144: 273-80.
DOI Google Scholar
62

Ding C, Yi X, Wu X, Bu X, Wang D, Wu Z, et al. Exosome-mediated transfer of circ RNA Circ NFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020; 479: 1-12.
DOI Google Scholar
63

Li Z, Meng X, Wu P, Zha C, Han B, Li L, et al. Glioblastoma cellderived lnc RNA-containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol Res. 2021; 9: 1383-99.
DOI Google Scholar
64

Wei QT, Liu BY, Ji HY, Lan YF, Tang WH, Zhou J, et al. Exosomemediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3k/AKT axis in gliomas. Mol Ther Oncolytics. 2021; 22: 114-28.
DOI Google Scholar
65

Zhang Z, Yin J, Lu C, Wei Y, Zeng A, You Y. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res. 2019; 38: 166.
DOI Google Scholar
66

Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Mechanism-based design of agents that selectively target drugresistant glioma. Science. 2022; 377: 502-11.
DOI Google Scholar
67

Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. 2019; 25: 4202-10.
DOI Google Scholar
68

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344: 1396-401.
DOI Google Scholar
69

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019; 178: 835-49.e21.
DOI Google Scholar
70

Muller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017; 18: 234.
DOI Google Scholar
71

Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 2017; 77: 2266-78.
DOI Google Scholar
72

Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014; 6: a021857.
DOI Google Scholar
73

Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, KantariMimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018; 115: E4041-50.
DOI Google Scholar
74

Fang Y, He Y, Wu C, Zhang M, Gu Z, Zhang J, et al. Magnetismmediated targeting hyperthermia-immunotherapy in “cold” tumor with CSF1R inhibitor. Theranostics. 2021; 11: 6860-72.
DOI Google Scholar
75

Rao R, Han R, Ogurek S, Xue C, Wu LM, Zhang L, et al. Glioblastoma genetic drivers dictate the function of tumorassociated macrophages/microglia and responses to CSF1Rinhibition. Neuro Oncol. 2022; 24: 584-97.
DOI Google Scholar
76

Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?Cell Stem Cell. 2015; 16: 225-38.
DOI Google Scholar
77

Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol. 2015; 31: 28-35.
DOI Google Scholar
78

Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29: 1203-17.
DOI Google Scholar
79

Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, et al. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 2021; 11: 665-83.
DOI Google Scholar
80

Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15: 501-13.
DOI Google Scholar
81

Torres A, Erices JI, Sanchez F, Ehrenfeld P, Turchi L, Virolle T, et al. Extracellular adenosine promotes cell migration/invasion of glioblastoma stem-like cells through A3 adenosine receptor activation under hypoxia. Cancer Lett. 2019; 446: 112-22.
DOI Google Scholar
82

Gargiulo G. Next-generation in vivo modeling of human cancers. Front Oncol. 2018; 8: 429.
DOI Google Scholar
83

Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000; 25: 55-7.
DOI Google Scholar
84

Rahme GJ, Luikart BW, Cheng C, Israel MA. A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma. Neuro Oncol. 2018; 20: 332-42.
DOI Google Scholar
85

Golebiewska A, Hau AC, Oudin A, Stieber D, Yabo YA, Baus V, et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathol. 2020; 140: 919-49.
DOI Google Scholar
86

Goranci-Buzhala G, Mariappan A, Gabriel E, Ramani A, RicciVitiani L, Buccarelli M, et al. Rapid and efficient invasion assay of glioblastoma in human brain organoids. Cell Rep. 2020; 31: 107738.
DOI Google Scholar
87

Tang M, Xie Q, Gimple RC, Zhong Z, Tam T, Tian J, et al. Threedimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Res. 2020; 30: 833-53.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 13 January 2023
Accepted: 22 March 2023
Published: 05 June 2023
Issue date: May 2023

Copyright

©2023 Cancer Biology & Medicine.

Rights and permissions

Creative Commons Attribution-NonCommercial 4.0 International License

Return